Together Pharma Ltd (TLV:TGTR)
Israel
· Delayed Price · Currency is ILS · Price in ILA 274.50
-4.40 (-1.58%)
Apr 28, 2026, 5:24 PM IDT
Together Pharma Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 109.63 | 96.05 | 91.01 | 31.23 | 12.03 | Upgrade
|
| Revenue Growth (YoY) | 14.13% | 5.55% | 191.42% | 159.67% | 7.16% | Upgrade
|
| Cost of Revenue | 78.14 | 78.54 | 56.38 | 37.12 | 14.2 | Upgrade
|
| Gross Profit | 31.49 | 17.51 | 34.62 | -5.89 | -2.17 | Upgrade
|
| Selling, General & Admin | 16.26 | 14.24 | 12.53 | 11.61 | 9.55 | Upgrade
|
| Other Operating Expenses | - | - | - | 2.27 | -1.71 | Upgrade
|
| Operating Expenses | 16.26 | 14.24 | 12.53 | 13.88 | 9.28 | Upgrade
|
| Operating Income | 15.23 | 3.27 | 22.09 | -19.77 | -11.46 | Upgrade
|
| Interest Expense | -6.73 | -9.38 | -19.59 | -17.2 | -14.8 | Upgrade
|
| Interest & Investment Income | - | 4.32 | - | - | 10.88 | Upgrade
|
| Earnings From Equity Investments | - | - | -0.25 | -0 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -2.87 | 0.48 | 0.54 | 1.76 | -0.41 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.75 | -0.9 | -1.25 | -1.11 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | 4.87 | -2.21 | 1.54 | -36.33 | -15.78 | Upgrade
|
| Pretax Income | 4.87 | -2.21 | 1.54 | -36.33 | -15.12 | Upgrade
|
| Income Tax Expense | 2.96 | -0.59 | 4.07 | -0.85 | - | Upgrade
|
| Earnings From Continuing Operations | 1.92 | -1.62 | -2.53 | -35.48 | -15.12 | Upgrade
|
| Net Income to Company | 1.92 | -1.62 | -2.53 | -35.48 | -15.12 | Upgrade
|
| Minority Interest in Earnings | -0.01 | 0.45 | -1.78 | 1.96 | 1.34 | Upgrade
|
| Net Income | 1.91 | -1.17 | -4.32 | -33.52 | -13.78 | Upgrade
|
| Net Income to Common | 1.91 | -1.17 | -4.32 | -33.52 | -13.78 | Upgrade
|
| Shares Outstanding (Basic) | 16 | 12 | 9 | 8 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 12 | 9 | 8 | 7 | Upgrade
|
| Shares Change (YoY) | 27.26% | 41.39% | 7.81% | 18.96% | 18.76% | Upgrade
|
| EPS (Basic) | 0.12 | -0.09 | -0.49 | -4.15 | -2.05 | Upgrade
|
| EPS (Diluted) | 0.12 | -0.09 | -0.49 | -4.18 | -2.23 | Upgrade
|
| Free Cash Flow | 5.17 | 1.37 | 13.97 | -14.07 | -20.17 | Upgrade
|
| Free Cash Flow Per Share | 0.33 | 0.11 | 1.59 | -1.73 | -2.94 | Upgrade
|
| Gross Margin | 28.72% | 18.23% | 38.04% | -18.86% | -18.07% | Upgrade
|
| Operating Margin | 13.89% | 3.41% | 24.28% | -63.30% | -95.27% | Upgrade
|
| Profit Margin | 1.74% | -1.22% | -4.74% | -107.35% | -114.55% | Upgrade
|
| Free Cash Flow Margin | 4.71% | 1.43% | 15.35% | -45.04% | -167.75% | Upgrade
|
| EBITDA | 21.28 | 8.93 | 27.62 | -14.37 | -6.14 | Upgrade
|
| EBITDA Margin | 19.41% | 9.30% | 30.34% | -46.01% | -51.04% | Upgrade
|
| D&A For EBITDA | 6.05 | 5.66 | 5.52 | 5.4 | 5.32 | Upgrade
|
| EBIT | 15.23 | 3.27 | 22.09 | -19.77 | -11.46 | Upgrade
|
| EBIT Margin | 13.89% | 3.41% | 24.28% | -63.30% | -95.27% | Upgrade
|
| Effective Tax Rate | 60.64% | - | 264.65% | - | - | Upgrade
|
| Advertising Expenses | 1.18 | 0.63 | 0.57 | 0.83 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.